The Global STD Testing Market Size is valued at USD 95 Billion in 2021 and is projected to reach a market size of USD 141 Billion by 2030; growing at a CAGR of 4.7%.
The significant prevalence of sexually transmitted diseases across the world primarily fuels the STD testing market revenue. The World Health Organization estimates that more than 1 million sexually transmitted infections are contracted each day throughout the world. As a result, the demand for the STD testing industry is growing substantially worldwide.
Sexually transmitted diseases (STDs) are infections that are passed from one person to another through sexual contact. STDs are frequently transmitted through oral, vaginal, or anal sex, claims Medline Plus. But studies have also revealed that STDs can spread via other types of intimate physical contact, like skin-to-skin contact. Sexually transmitted diseases also commonly known as sexually transmitted infections (STIs) can be caused by viruses, bacteria, and parasites. Women are more susceptible to STDs, particularly during pregnancy
Global STD Testing Market DRO’s:
|Market||STD Testing Market|
|Market Size 2021||USD 95 Billion|
|Market Forecast 2030||USD 141 Billion|
|CAGR During 2022 - 2030||4.7%|
|Analysis Period||2018 - 2030|
|Forecast Data||2022 - 2030|
|Segments Covered||By Disease Type, By Location of Testing, And By Geography
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Abbott Laboratories, Affymetrix, Alere Inc., bioMérieux, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Cepheid Inc., Danaher Corporation, DiaSorin, Hologic Inc., Orasure, and Roche Holdings AG.|
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
10 hrs of free customization and expert consultation
The growing prevalence of STDs around the world is the primary driver of the industry. According to the World Health Organization, over 374 million new infections are acquired among people each year. Chlamydia, syphilis, gonorrhea, and trichomoniasis are the most common. It is also estimated that 500 million people between the ages of 15 and 49 are infected with the herpes simplex virus in their genital area (HSV). As a result, the value of the STD testing market is multiplying as the number of patients increases around the world.
Another factor driving the STD testing market is increased patient awareness and favorable government support for testing. Adolescents and young adults between the ages of 15 and 24 are more vulnerable to STIs than older adults. According to the World Health Organization, 20% of HIV/AIDS patients are in their twenties, and one out of every twenty adolescents contracts an STI each year. Youths are more likely than adults to engage in unprotected sex, have multiple sexual partners, and engage in transgenerational and transactional sex. The Centers for Disease Control and Prevention (CDC) recommends that sexually active people get tested for STDs. Furthermore, all adolescents and adults aged 13 to 64 should be tested for HIV at least once. Every year, all sexually active women under the age of 25 should be tested for gonorrhea and chlamydia. Additionally, all pregnant women should be tested for HIV, syphilis, hepatitis B, and C.
However, the social stigma associated with these tests prevents the market from expanding. According to the WHO, barriers to bigger and more effective use of these treatments include a lack of public awareness, a lack of training among health workers, and a long-standing, widespread stigma surrounding STIs. However, a large proportion of sexually infected people live in remote areas where rapid testing is not feasible, resulting in a lack of testing. This factor also inhibits market growth.
Furthermore, rising government initiatives in various countries are expected to generate a plethora of growth opportunities for the market in the coming years. The National Aids Control Programme (NACP) IV, initiated by the National Aids Control Organization (NACO), is an HIV/AIDS prevention and control programme in India. The NACP IV programme aimed to provide universal and standardized high-quality STI/RTI services in all healthcare settings. Furthermore, NACO offers free standardized STI/RTI services to the public. As a result, favorable government initiatives are assisting the STD testing market to grow positively, particularly in India, Indonesia, Thailand, and African countries, among others.
STD Testing Market Segmentation
The worldwide STD testing market is split based on disease type, location of testing, and geography.
Market by Disease Type
According to our STD testing market forecast, chlamydia STD Testing generated the maximum market share in 2021 and is expected to continue its trend during the forecast timeframe from 2022 to 2030. Chlamydia (Chlamydia trachomatis) is the most common sexually transmitted infection in the world. In 2019, the CDC received reports of 1,808,703 cases of Chlamydia trachomatis infection, making it the most common reportable condition in the United States. Adolescents and young adults have the highest rates of reported chlamydia. In 2019, nearly two-thirds (61%) of all reported chlamydia cases were in people aged 15 to 24.
Market by Location of Testing
According to our STD testing industry analysis, laboratory testing took the lead in 2021 and is expected to continue to do so in the future because most diagnostic testing is done in labs. Furthermore, laboratory testing yields more precise results than point-of-care testing. However, due to the quick and easy testing in this environment, the point of care testing sub-segment is expected to grow at the fastest rate in the coming years.
STD Testing Market Regional Outlook
The Middle East & Africa (MEA)
The growing prevalence of STDs in Asia-Pacific fuels the regional STD testing market growth
Based on our STD testing market outlook, the Asia-Pacific region accounted for a significant share of the market from 2022 to 2030. The rising number of STD patients in emerging countries such as China, India, Indonesia, Philippines, and Indonesia are primarily driving the Asia-Pacific STD testing market. Additionally, the rising awareness among people via education campaigns, increasing alertness among the youth population, and increasing government initiatives for STD testing are other factors fueling the Asia-Pacific market growth.
North America is expected to hold a dominant position in the global market due to the presence of technologically advanced products, and the presence of FDA-approved STD testing devices in the region. Furthermore, the provision of insurance coverage policies and the emergence of novel POC testing concepts are some of the factors that are supporting the North America STD testing market.
STD Testing Market Players
Some of the top STD testing companies offered in the professional report include Abbott Laboratories, Affymetrix, Alere Inc., bioMérieux, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Cepheid Inc., Danaher Corporation, DiaSorin, Hologic Inc., Orasure, and Roche Holdings AG.
The estimated value of global STD testing market in 2021 was accounted to be USD 95 Billion.
The projected CAGR STD testing market during the analysis period of 2022 to 2030 is 4.7%.
The prominent players of the global STD Testing market are Abbott Laboratories, Affymetrix, Alere Inc., bioMérieux, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Cepheid Inc., Danaher Corporation, DiaSorin, Hologic Inc., Orasure, and Roche Holdings AG.
Asia-Pacific held the dominating STD testing during the analysis period of 2022 to 2030.
North America region exhibited fastest growing CAGR for STD testing during the analysis period of 2022 to 2030.
Increasing prevalence of sexually transmitted diseases, growing patient awareness and favorable support for testing, and rising government initiatives drives the growth of global STD testing market.
Based on disease type, Chlamydia segment held the maximum share STD testing market in 2021.